Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results

April 26, 2011 By Bio-Medicine.Org

SEATTLE, April 27, 2011 /PRNewswire/ — Cell Therapeutics, Inc.
(“CTI” or the “Company”) (NASDAQ and MTA: CTIC) today reported
accomplishments and financial results for the first quarter ended
March 31, 2011.

“In the first quarter, we raised $50 million through two
financings, advanced pixantrone into a confirmatory pivotal trial
and acquired an exclusive license from Chroma Therapeutics Ltd.
(“Chroma”) to co-develop and market Chroma’s drug candidate,
tosedostat, in the Americas all while reducing operating expenses
compared to the same period last year,” said James A. Bianco, M.D.,
Chief Executive Officer of CTI. “In March, we received the day 120
list of questions from the European Medicines Agency (“EMA”) for
our Marketing Authorization Application (“MAA”) for pixantrone in
Europe and are pleased with the review progress and the potential
for a recommendation from the EMA’s Medicinal Product Committee
before the end of this year. We also expect to hear from the Office
of New Drugs (“OND”) this quarter relating to our appeal of the
decision made on our New Drug Application (“NDA”) for pixantrone.
With an impressive portfolio of novel phase III drug candidates and
the potential for regulatory approval for pixantrone, this year
could be a pivotal year for the Company.”

Review of 2011 Key Accomplishments

Completed two financings at a total offering price of $50 million
in the first quarter 2011 Entered into a co-development and license
agreement with Chroma, which is located in the United Kingdom.
 This agreement provides CTI with exclusive marketing and
co-development rights to Chroma’s drug candidate, tosedostat, in
North, Central and South America. Tosedostat is an oral, tumor
selective inducer of amino acid depletion responses that has
demonstrated encouraging single agent anti-tumor responses in
blood-related cancers and solid tumors in phase I-II clinical
trials. Initiated a pivotal trial of pixantrone for the trea

‘/>”/>

SOURCE

Related Articles Read More >

Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech